Peptide LibraryTriptorelin dosage in published studies and labels
These are the doses used for Triptorelin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Triptorelin has FDA-approved human dosages given as an intramuscular injection. For advanced prostate cancer, TRELSTAR is 3.75 mg every 4 weeks, 11.25 mg every 12 weeks or 22.5 mg every 24 weeks. For central precocious puberty in children aged 2 and over, TRIPTODUR is 22.5 mg every 24 weeks.
| Human dosing established | Yes |
|---|---|
| Route | Intramuscular |
| Frequency | Every 4, 12 or 24 weeks by strength |
| Duration studied | Long-term for prostate cancer; until the age of puberty for central precocious puberty |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — TRELSTAR, advanced prostate cancerFDA-approved label · FDA prescribing information | Men with advanced prostate cancer | 3.75 mg every 4 weeks, 11.25 mg every 12 weeks or 22.5 mg every 24 weeks | Intramuscular, either buttock | Every 4, 12 or 24 weeks by strength | Long-term | Treatment of advanced prostate cancer | TRELSTAR (triptorelin pamoate for injectable suspension) — FDA prescribing information (Verity), DailyMed |
| FDA label — TRIPTODUR, central precocious pubertyFDA-approved label · FDA prescribing information | Children aged 2 and over with central precocious puberty | 22.5 mg | Intramuscular | Once every 24 weeks | Stopped at the appropriate age for the onset of puberty | Suppression of LH and sex steroids | TRIPTODUR (triptorelin) for extended-release injectable suspension — FDA prescribing information (Azurity), DailyMed |
| Phase 3 trial of the 6-month formulation in Chinese children (Yu et al., 2024)Clinical trial · Phase 3 open-label single-arm trial (NCT05029622) | Chinese children with central precocious puberty (girls under 9, boys under 10; 66 completed) | Triptorelin pamoate 22.5 mg on day 1 and at month 6 | Not stated in the indexed abstract | Every 6 months | 12 months | All patients had LH suppression (stimulated peak LH 5 IU/L or less) at month 6; 98.5% at month 12 | Yu X et al. A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty. Adv Ther. 2024. |
Where sources disagree
- The TRELSTAR strengths have different release characteristics: the label says they are not additive and must be chosen by the dosing schedule wanted.
- The TRELSTAR label warns of hypersensitivity reactions including anaphylactic shock, tumor flare in the first weeks, and metabolic changes such as hyperglycemia and diabetes. The TRIPTODUR label also warns of pseudotumor cerebri.
- OvuGel, also listed on DailyMed under triptorelin, is a veterinary gel for sows. It is not a human product and contributes no dosing here.